Company intelligence / Profile preview

Cambridge Interventional

Burlington, Massachusetts, United Statescambridgeinterventional.com ↗

Ownership: Private
Development stage: Other

Overview

Cambridge Interventional develops, manufactures, and markets innovative radiofrequency ablation systems for minimally invasive treatment of thyroid nodules, tumors, and bone lesions. Their CRF system is FDA approved and CE marked. The company leverages decades of experience in RFA technology development by the Cosman family. Clinical results cited include reproducible large-volume tissue ablations with real-time monitoring capabilities.

Therapeutic areas: EndocrinologyOncology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Distributed internationally via partners such as Ab Medica in Italy.

Beyond the preview

Go deeper on Cambridge Interventional.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cambridge Interventional.

Explore the full profile